A Phase 3 interventional study of Sotatercept and Placebo in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 120 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 3rd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Kazuya Hosokawa · Sites in Japan
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18–70
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
By country, each count listing its studies:
sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2021.
This study's enrollment of 324 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc: 3 open now, 5 under way, 1 of them phase 3. Of 12 finished, 11 (92%) have results posted.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 7th registered.
Merck & Co., Inc’s Pulmonary Arterial Hypertension studies by the year they started, since 2013.
1 of the studies testing sotatercept in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356778Kazuya HosokawaA Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, from their registry updates:
Among Merck & Co., Inc’s 17 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH. The primary hypothesis of the study is that the participants receiving sotatercept will have improved 6-minute walk distance (6MWD) at 24 weeks compared to participants receiving placebo.
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study in subjects with symptomatic PAH who present with idiopathic or heritable PAH, PAH associated with connective tissue diseases (CTD), drug or toxin induced, post shunt correction PAH, or PAH presenting at least 1 year following the correction of congenital heart defects (CHDs), and currently on background PAH therapy.
The primary efficacy endpoint of the study is exercise capacity, as measured by the 6-minute walk distance (6MWD) measured at 24 week following initiation of treatment.
Study duration will be approximately 2 years. A stratified Wilcoxon test will be used for analysis of the primary endpoint, with appropriate imputation for missing data, as detailed in the Statistical Analysis Plan. An unblinded, external, independent Data Monitoring Committee (DMC) will monitor participant safety throughout the course of the study. Participants completing this study will be eligible to receive sotatercept in a separate, open-label extension study.
Key Inclusion Criteria:
Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of World Health Organization (WHO) pulmonary arterial hypertension (PAH) Group 1 in any of the following subtypes:
On stable doses of background PAH therapy and diuretics (i.e., patient-specific dose goal for each therapy already achieved) for at least 90 days prior to screening; for infusion prostacyclins, dose adjustment within 10% of optimal dose is allowed per medical practice
Females of must:
Key Exclusion Criteria:
Any of the following clinical laboratory values at the screening visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy
Biological: Sotatercept · Drug: Background PAH Therapy
Placebo administered (SC) every 21 days plus background PAH therapy
Drug: Placebo · Drug: Background PAH Therapy
Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
Also known as: MK-7962, ACE-011
Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24
The 6MWD was the distance walked in 6 minutes as a measure of functional capacity. This was assessed using the 6-minute walk test (6MWT). Per protocol, change from baseline in 6MWD at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a study participant administered a study drug, which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it was considered related to the study drug. Per protocol, the number of participants who reported an AE were reported for DBPC period.
Time frame: Up to approximately 24 weeks
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a study participant administered a study drug, which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it was considered related to the study drug. Per protocol, the number of participants who discontinued study treatment due to an AE were reported for DBPC period.
Time frame: Up to approximately 24 weeks
Change From Baseline in the Percentage of Participants Achieving Multicomponent Improvement at Week 24
Multicomponent Improvement was defined as consisting of all of the following: (a) Improvement in 6MWD (increase ≥30 meters) (b) Improvement in N-terminal pro b-type natriuretic peptide (NT-proBNP; decrease in NT-proBNP ≥30%) or maintenance/achievement of NT-proBNP level \<300 ng/L (c) Improvement in World Health Organization (WHO) Functional Class (FC) or maintenance of WHO FC II. Per protocol, change from baseline in the percentage of participants achieving multicomponent improvement at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
PVR is a hemodynamic variable of pulmonary circulation and was measured by right heart catheterization (RHC). Per protocol, the change from baseline in PVR at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Change From Baseline in NT-proBNP Levels at Week 24
NT-proBNP is a circulating biomarker that reflects myocardial stretch. Per protocol, the change from baseline in NT-proBNP level at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Change From Baseline in the Percentage of Participants Who Improve in WHO FC at Week 24
The severity of participant's pulmonary arterial hypertension (PAH) symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. Per protocol, change from baseline in the percentage of participants who improve in WHO FC at Week 24 were reported for DBPC period.
Time frame: Baseline and Week 24
Time to Death or the First Occurrence of Clinical Worsening Event
Clinical Worsening events are defined as any of the following: worsening-related listing for lung and/or heart transplant; need to initiate rescue therapy with an approved background PAH therapy or the need to increase the dose of infusion prostacyclin by 10% or more; need for atrial septostomy; hospitalization for worsening of PAH (≥ 24 hours); or deterioration of PAH defined by both of the following events occurring at any time: worsened WHO FC and decrease in 6MWD by ≥15% confirmed by 2 tests at least 4 hours apart, but no more than 1 week. Per protocol, time to death or the first occurrence of clinical worsening event was reported.
Time frame: Up to approximately 18 months
Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator at Week 24
The simplified French risk scoring system was based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension (PH). In this study, the noninvasive parameters were used to determine the score. 'Low risk' was defined as attaining or maintaining all 3 low-risk criteria: WHO FC I or II, 6MWD \> 440 m, and NT-proBNP \<300 ng/L. Per protocol, change from baseline in percentage of participants who maintained or achieved a low risk score using the simplified French risk score calculator at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®) at Week 24
The PAH SYMPACT is a 23-item questionnaire to measure pulmonary arterial hypertension (PAH)-related symptoms and impact of PAH on daily life. The physical impact domain consists of walking slowly on a flat surface, walking quickly on a flat surface, walking uphill, carrying things, doing light indoor household chores, washing, or dressing oneself, and needing help from others. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no physical impact to 4=severe physical impact). A higher score indicated more severe physical impact. Per protocol, change from baseline in the physical impacts domain score at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT® at Week 24
The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The cardiopulmonary symptoms consist of shortness of breath, fatigue, lack of energy, swelling in the ankles or legs, swelling in the stomach area, and cough. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (no symptom at all) to 4 (very severe symptoms). The mean individual symptom item score was determined for each of the 6 items and a domain score was calculated by summing the mean individual symptom item scores and dividing by the number of items (range: 0=no cardiopulmonary symptoms to 4=severe cardiopulmonary symptoms). A higher score indicated more severe symptoms experienced. Per protocol, change from baseline in the cardiopulmonary domain score at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT® at Week 24
The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The Cognitive/Emotional Impact domain consists of thinking clearly, feeling sad, feeling worried, and feeling frustrated. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no cognitive/emotional impact to 4=severe cognitive/emotional impact). A higher score indicated more severe cognitive/emotional impact. Per protocol, change from baseline in the cognitive/emotional impacts domain score at Week 24 was reported for DBPC period.
Time frame: Baseline and Week 24
Of the 324 randomized participants, 1 participant was randomized in error and did not receive study treatment and no data was collected. Hence, the results are presented on 323 participants.
| Milestone | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy |
|---|---|---|
| Started | 163 | 160 |
| Treated | 163 | 160 |
| Completed | 159 | 148 |
| Not completed | 4 | 12 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Death | 0 | 5 |
| Withdrew: Clinical worsening event | 0 | 2 |
| Milestone | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy |
|---|---|---|
| Started | 159 | 142 |
| Treated | 158 | 142 |
| Completed | 155 | 136 |
| Not completed | 4 | 6 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
The 6MWD was the distance walked in 6 minutes as a measure of functional capacity. This was assessed using the 6-minute walk test (6MWT). Per protocol, change from baseline in 6MWD at Week 24 was reported for DBPC period.
| meters | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 | 34.4 (32.5 to 35.5) | 1.0 (-1.0 to 5.0) |
An AE was any untoward medical occurrence in a study participant administered a study drug, which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it was considered related to the study drug. Per protocol, the number of participants who reported an AE were reported for DBPC period.
| Participants | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 138 | 140 |
An AE was any untoward medical occurrence in a study participant administered a study drug, which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it was considered related to the study drug. Per protocol, the number of participants who discontinued study treatment due to an AE were reported for DBPC period.
| Participants | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 3 | 10 |
Multicomponent Improvement was defined as consisting of all of the following: (a) Improvement in 6MWD (increase ≥30 meters) (b) Improvement in N-terminal pro b-type natriuretic peptide (NT-proBNP; decrease in NT-proBNP ≥30%) or maintenance/achievement of NT-proBNP level \<300 ng/L (c) Improvement in World Health Organization (WHO) Functional Class (FC) or maintenance of WHO FC II. Per protocol, change from baseline in the percentage of participants achieving multicomponent improvement at Week 24 was reported for DBPC period.
| Percent change | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in the Percentage of Participants Achieving Multicomponent Improvement at Week 24 | 38.9 | 10.1 |
PVR is a hemodynamic variable of pulmonary circulation and was measured by right heart catheterization (RHC). Per protocol, the change from baseline in PVR at Week 24 was reported for DBPC period.
| dynes*sec/cm^5 | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24 | -165.1 (-184.0 to -152.0) | 32.8 (24.0 to 40.0) |
NT-proBNP is a circulating biomarker that reflects myocardial stretch. Per protocol, the change from baseline in NT-proBNP level at Week 24 was reported for DBPC period.
| pg/mL | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DPBC Period) |
|---|---|---|
| Change From Baseline in NT-proBNP Levels at Week 24 | -230.3 (-236.0 to -223.0) | 58.6 (44.0 to 73.0) |
The severity of participant's pulmonary arterial hypertension (PAH) symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. Per protocol, change from baseline in the percentage of participants who improve in WHO FC at Week 24 were reported for DBPC period.
| Percent change | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in the Percentage of Participants Who Improve in WHO FC at Week 24 | 29.4 | 13.8 |
Clinical Worsening events are defined as any of the following: worsening-related listing for lung and/or heart transplant; need to initiate rescue therapy with an approved background PAH therapy or the need to increase the dose of infusion prostacyclin by 10% or more; need for atrial septostomy; hospitalization for worsening of PAH (≥ 24 hours); or deterioration of PAH defined by both of the following events occurring at any time: worsened WHO FC and decrease in 6MWD by ≥15% confirmed by 2 tests at least 4 hours apart, but no more than 1 week. Per protocol, time to death or the first occurrence of clinical worsening event was reported.
| Weeks | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy |
|---|---|---|
| Time to Death or the First Occurrence of Clinical Worsening Event | NA ± NA | NA ± NA |
The simplified French risk scoring system was based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension (PH). In this study, the noninvasive parameters were used to determine the score. 'Low risk' was defined as attaining or maintaining all 3 low-risk criteria: WHO FC I or II, 6MWD \> 440 m, and NT-proBNP \<300 ng/L. Per protocol, change from baseline in percentage of participants who maintained or achieved a low risk score using the simplified French risk score calculator at Week 24 was reported for DBPC period.
| Percent Change | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator at Week 24 | 39.5 | 18.2 |
The PAH SYMPACT is a 23-item questionnaire to measure pulmonary arterial hypertension (PAH)-related symptoms and impact of PAH on daily life. The physical impact domain consists of walking slowly on a flat surface, walking quickly on a flat surface, walking uphill, carrying things, doing light indoor household chores, washing, or dressing oneself, and needing help from others. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no physical impact to 4=severe physical impact). A higher score indicated more severe physical impact. Per protocol, change from baseline in the physical impacts domain score at Week 24 was reported for DBPC period.
| Score on a scale | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®) at Week 24 | -0.13 (-0.15 to 0.00) | 0.01 (0.00 to 0.14) |
The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The cardiopulmonary symptoms consist of shortness of breath, fatigue, lack of energy, swelling in the ankles or legs, swelling in the stomach area, and cough. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (no symptom at all) to 4 (very severe symptoms). The mean individual symptom item score was determined for each of the 6 items and a domain score was calculated by summing the mean individual symptom item scores and dividing by the number of items (range: 0=no cardiopulmonary symptoms to 4=severe cardiopulmonary symptoms). A higher score indicated more severe symptoms experienced. Per protocol, change from baseline in the cardiopulmonary domain score at Week 24 was reported for DBPC period.
| Score on a scale | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in the Cardiopulmonary Symptoms Domain Score of PAH-SYMPACT® at Week 24 | -0.12 (-0.14 to -0.06) | -0.01 (-0.03 to 0.02) |
The PAH SYMPACT is a 23-item questionnaire to measure PAH-related symptoms and impact of PAH on daily life. The Cognitive/Emotional Impact domain consists of thinking clearly, feeling sad, feeling worried, and feeling frustrated. Participants were asked to recall and report on each item experienced in past 7 days. Score for each item ranges from 0 (not difficult at all) to 4 (extremely difficult). A domain score was calculated by summing the individual responses for each item and dividing by the number of impact items (range: 0=no cognitive/emotional impact to 4=severe cognitive/emotional impact). A higher score indicated more severe cognitive/emotional impact. Per protocol, change from baseline in the cognitive/emotional impacts domain score at Week 24 was reported for DBPC period.
| Score on a scale | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) |
|---|---|---|
| Change From Baseline in the Cognitive/Emotional Impacts Domain Score of PAH-SYMPACT® at Week 24 | 0.00 (0.00 to 0.00) | 0.000007 (0.00 to 0.0006) |
Collected over Up to approximately 19 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotatercept Plus Background PAH Therapy (DBPC Period) | 0/163 (0%) | 23/163 (14.1%) | 111/163 (68.1%) |
| Placebo Plus Background PAH Therapy (DBPC Period) | 6/160 (3.8%) | 36/160 (22.5%) | 88/160 (55%) |
| Sotatercept Plus Background PAH Therapy (LTDB Period) | 2/159 (1.3%) | 26/158 (16.5%) | 82/158 (51.9%) |
| Placebo Plus Background PAH Therapy (LTDB Period) | 1/142 (0.7%) | 14/142 (9.9%) | 50/142 (35.2%) |
| Event | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) | Sotatercept Plus Background PAH Therapy (LTDB Period) | Placebo Plus Background PAH Therapy (LTDB Period) |
|---|---|---|---|---|
| HypervolaemiaMetabolism and nutrition disorders | 0/163 | 1/160 | 0/158 | 2/142 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 1/163 | 2/160 | 0/158 | 2/142 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/163 | 0/160 | 2/158 | 0/142 |
| Vascular device occlusionGeneral disorders | 0/163 | 0/160 | 2/158 | 0/142 |
| COVID-19Infections and infestations | 0/163 | 2/160 | 2/158 | 0/142 |
| Catheter site infectionInfections and infestations | 0/163 | 0/160 | 2/158 | 0/142 |
| PneumoniaInfections and infestations | 1/163 | 0/160 | 2/158 | 0/142 |
| Cardiac arrestCardiac disorders | 0/163 | 2/160 | 0/158 | 0/142 |
| Right ventricular failureCardiac disorders | 0/163 | 2/160 | 0/158 | 1/142 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/163 | 2/160 | 0/158 | 0/142 |
| Event | Sotatercept Plus Background PAH Therapy (DBPC Period) | Placebo Plus Background PAH Therapy (DBPC Period) | Sotatercept Plus Background PAH Therapy (LTDB Period) | Placebo Plus Background PAH Therapy (LTDB Period) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 33/163 | 24/160 | 9/158 | 6/142 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 20/163 | 3/160 | 25/158 | 1/142 |
| COVID-19Infections and infestations | 24/163 | 19/160 | 24/158 | 21/142 |
| DiarrhoeaGastrointestinal disorders | 20/163 | 12/160 | 6/158 | 3/142 |
| NauseaGastrointestinal disorders | 17/163 | 17/160 | 8/158 | 3/142 |
| FatigueGeneral disorders | 17/163 | 12/160 | 10/158 | 4/142 |
| DizzinessNervous system disorders | 17/163 | 3/160 | 6/158 | 7/142 |
| TelangiectasiaSkin and subcutaneous tissue disorders | 17/163 | 5/160 | 12/158 | 2/142 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/163 | 12/160 | 2/158 | 6/142 |
| Injection site painGeneral disorders | 11/163 | 10/160 | 0/158 | 1/142 |
Of the 324 participants randomized in the study, one participant was randomized in error in placebo plus background PAH therapy arm and no data was collected on this participant. Per protocol, this participant was excluded from the study analysis.
| Age, Continuous(Years) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| Mean | 47.6 ± 14.09 | 48.3 ± 15.50 | 47.9 ± 14.79 |
| Sex: Female, Male(Participants) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| Female | 129 | 127 | 256 |
| Male | 34 | 33 | 67 |
| Ethnicity (NIH/OMB)(Participants) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 31 | 58 |
| Not Hispanic or Latino | 132 | 124 | 256 |
| Unknown or Not Reported | 4 | 5 | 9 |
| Race (NIH/OMB)(Participants) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 1 | 6 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 2 | 5 | 7 |
| White | 147 | 141 | 288 |
| More than one race | 7 | 4 | 11 |
| Unknown or Not Reported | 6 | 2 | 8 |
| 6-Minute Walk Distance (6MWD) at baseline(meters) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| Mean | 397.6 ± 84.28 | 404.7 ± 80.59 | 401.1 ± 82.4 |
| World Health Organization (WHO) functional class (FC) II or III at baseline(Participants) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| Class II | 79 | 78 | 157 |
| Class III | 84 | 82 | 166 |
| Background PAH Therapy at Baseline(Participants) | Sotatercept Plus Background PAH Therapy | Placebo Plus Background PAH Therapy | Total |
|---|---|---|---|
| Monotherapy | 9 | 4 | 13 |
| Double therapy | 56 | 56 | 112 |
| Triple therapy | 98 | 100 | 198 |
Showing the first 100 of 120 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2021 to primary completion in Aug 2022, 19 months.
Results were first posted in Aug 2023, 11 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 19 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Pulmonary Arterial Hypertension →
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA →